Lineage Cell Therapeutics, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported revenue was USD 8.95 million compared to USD 14.7 million a year ago. Net loss was USD 21.49 million compared to USD 26.27 million a year ago.

Basic loss per share from continuing operations was USD 0.12 compared to USD 0.15 a year ago.